Clinical Trial Finder

Inclusion Criteria:

• - Patients must have Eastern Cooperative Oncology Group (ECOG) =< 3.

• - All patients must have histologic evidence suggesting small cell lung cancer.

Histologic confirmation may be from the primary tumor site, or from another metastatic site (systemic lymph node, etc.). Cytology-alone is not an acceptable method of diagnosis.

• - Patient has 10 or less brain metastases on contrast-enhanced brain MRI scan obtained no greater than 6 weeks prior to study registration.

Biopsy of brain metastasis is not required. A patient may be enrolled with zero brain metastasis assuming that the SRS is to be directed at the post-operative surgical cavity of a resected metastasis.

• - Patients must be eligible to have all lesions treated with stereotactic radiosurgery as determined by the study radiation oncologist.

• - Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital.

• - Patients should have normal coagulation [International Normalized Ratio (INR) < 1.3].

within 28 days of enrollment.

• - Patient's primary language is English.

• - No prior radiation therapy to the brain, including WBRT, PCI, or SRS.

• - Performance Status Assessment.

• - Standard ECOG performance status assessment will be used and determined by the treating physician.

Exclusion Criteria:

• - Patients are excluded if they have a history of metastatic cancer in addition to small cell malignancy or a history of uncontrolled non-metastatic cancer.

Patients with localized squamous cell carcinoma and/or basal cell carcinoma are not excluded.

• - Patients are excluded if there is radiographic evidence of leptomeningeal disease.

• - Patients are excluded if there are malignant cells identified in the CSF on cytologic examination.

• - Patients are not excluded for circulating tumor deoxyribonucleic acid (DNA) (ctDNA) found in the CSF.

• - Female patients of childbearing age are excluded if they are pregnant as determined with a urine or serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breast-feeding.

• - Patients are excluded if they are unable to obtain an MRI scan for any other reason, including gadolinium allergy.

• - Patients are excluded with medical history of a psychiatric or neurologic illness, or other comorbidities believed to affect cognitive function.

Subjects with neurocognitive deficit related to brain metastasis are an exception to this criterion and may qualify for the study.

PRIMARY OBJECTIVE:

• I. To estimate the cognitive decline rate at 3 months.

SECONDARY OBJECTIVES:

• I. To examine cognitive decline rate on each individual cognitive test at each time point.

• II. To examine cognitive decline rates using reliable change index methodology.

• III. To report the overall survival of patients (death due to any cause) of patients receiving stereotactic radiosurgery (SRS) for small cell lung cancer (SCLC) brain metastasis.

• IV. To report rates of local tumor control (of the treated lesions) in the brain post-treatment, as dictated by magnetic resonance imaging (MRI) surveillance schedule above.

• V. To report distant tumor control in the brain (of non-treated lesions) post-treatment, as dictated by MRI surveillance schedule above.

• VI. To report time elapsed from SRS to whole brain radiation therapy (WBRT).

• VII. To report rate of intracranial toxicity of SRS in the setting of prior WBRT.

• VIII. To report rates of intracranial toxicity of concurrent atezolizumab with SRS.

• IX. To determine rates of systemic and intracranial disease control (time to progression) in those who are treated concurrently with atezolizumab and SRS.

• X. To determine the rates of SCLC-specific survival.

XI. To assess the pre-treatment factors and baseline characteristics in the predictive determination of local control, intracranial control, systemic control, and neurocognitive outcomes. XII. To assess the correlation between number of lesions and total volume of intracranial disease and neurocognitive outcome. XIII. To document post-treatment intracranial toxicity profile in patients after SRS. CORRELATIVE OBJECTIVE:

• I. Cerebral spinal fluid (CSF) biomarkers.

OUTLINE: Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion. After completion of study treatment, patients are followed up at 1, 3, 6, 9, 12, 16, 20, 24, 30, and 36 months after SRS.

Arms

Experimental: Treatment (SRS)

Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.

Interventions

Other: - Questionnaire Administration

Ancillary studies

Radiation: - Stereotactic Radiosurgery

Undergo SRS